Blinatumomab, a BiTE targeting CD3 and CD19, has shown efficacy in treating patients with rheumatoid arthritis (RA); six patients with multidrug-resistant RA observed B cell depletion and a swift reduction in clinical disease activity (189). The gene discussed is CD19; the disease is rheumatoid arthritis.